Biologics in the management of childhood atopic dermatitis - 03/03/23
Doi : 10.1016/j.jaci.2023.01.010
Sneha Butala, MD a, b, Amy S. Paller, MD a, b, ⁎ 
a Department of Dermatology, Northwestern University, Chicago, Ill
b Department of Pediatrics, Feinberg School of Medicine, Northwestern University, Chicago, Ill
∗Corresponding author: Amy S. Paller, MD, 676 N. St. Clair St, 16th Floor, Chicago, IL 60611.676 N. St. Clair St16th FloorChicagoIL60611
Key words : Atopic dermatitis, eczema, biologics, dupilumab, lebrikizumab, tralokinumab, IL-4, IL-13, cytokine signaling, Janus kinase inhibitor
Le texte complet de cet article est disponible en PDF.
Plan
| Disclosure of potential conflict of interest: A. S. Paller has been an investigator for AbbVie, AnaptysBio, Eli Lilly, Incyte, Janssen, KrystalBio, Regeneron, and UCB; a consultant with honoraria from AbbVie, Acrotech, Almirall, Amgen, Amryt, Arcutis, Arena, Azitra, BioCryst, BiomX, Bridgebio, Bristol-Myers Squibb, Castle Biosciences, Catawba, Eli Lilly, Exicure, Gilead, Incyte, Janssen, Johnson & Johnson, Kamari, Leo, Novartis, OM Pharma, Pfizer, Pierre Fabre, RAPT, Regeneron, Sanofi/Genzyme, Seanergy, and UCB; and a data safety monitoring board member for AbbVie, Abeona, Bausch, Galderma, Inmed, and Novan. The remaining author declares that she has no relevant conflicts of interest. |
© 2023
American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 151 - N° 3
P. 681-685 - mars 2023 Retour au numéro
Article précédent
- News beyond our pages
- Marc E. Rothenberg, Jean Bousquet
- Immunodeficiency secondary to biologics
- Roxane Labrosse, Elie Haddad
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?